CDASI作为皮肌炎临床结局工具的有效性与实用性:综合综述
CDASI具有评定者内和评定者间信度、效度、可重复性、对临床变化的敏感性及易用性,与Skindex-29生活质量及IFN-β相关,是经验证的结局工具。
要点
- CDASI具有评定者内和评定者间信度、效度、可重复性及对临床变化的敏感性。
- CDASI与Skindex-29生活质量测量及IFN-β显著相关。
- CDASI是经验证的皮肌炎疾病测量工具,可用于临床试验。
核心结论
- CDASI是经验证的皮肌炎疾病测量工具,已显示为临床试验中有效的结局工具。
主要发现
- CDASI具有评定者内和评定者间信度、效度、可重复性、对临床变化的敏感性及易用性。
- CDASI与Skindex-29生活质量测量相关。
- CDASI活动度评分与IFN-β显著相关。
临床怎么用
- CDASI可用于临床试验和纵向监测皮肌炎疾病进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Validated outcome measures are paramount in the assessment of disease progression and evaluation of new therapeutics in clinical trials. Dermatomyositis (DM) is an autoimmune disease that is frequently refractory to current therapies and warrants the development of new treatments. The Cutaneous Disease Area and Severity Index (CDASI) was developed in 2008 in response to a need for a reliable, validated measure of skin disease activity and damage for use in clinical trials and longitudinal monitoring of disease progression. METHODS: The literature was searched for all studies validating and utilizing the CDASI between 2008 and October 2018 using searches in PubMed. Studies pertaining to validation of the CDASI, correlation with quality of life, use in the evaluation of current therapies and ongoing trials, as well as relationships to biomarkers were included in this review. RESULTS: The CDASI was found to have intra- and inter-rater reliability, validity, reproducibility, sensitivity to clinical changes, and ease of use. It has been shown to correlate with quality of life as measured by the Skindex-29 outcome measure. The CDASI activity score has additionally been shown to correlate significantly with IFN-β, a key cytokine in DM pathogenesis. CONCLUSION: The CDASI is a validated measure of dermatomyositis disease and has been shown to be an effective outcome instrument in clinical trials.
引用
- Ahmed S, Chen KL, Werth VP, et al. The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: A comprehensive review. Semin Arthritis Rheum. 2020. PMID: 32057402. doi:10.1016/j.semarthrit.2020.01.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。